Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
Liu, X., Onda, M., Watson, N., Hassan, R., Ho, M., Bera, T.K., Wei, J., Chakraborty, A., Beers, R., Zhou, Q., Shajahan, A., Azadi, P., Zhan, J., Xia, D., Pastan, I.(2022) Proc Natl Acad Sci U S A 119: e2202439119-e2202439119
- PubMed: 35512094 
- DOI: https://doi.org/10.1073/pnas.2202439119
- Primary Citation of Related Structures:  
7U8C - PubMed Abstract: 
SignificanceMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical development.
Organizational Affiliation: 
Laboratory of Molecular Biology, National Cancer Institute (NCI), Bethesda, MD 20892-4264.